Trial Profile

A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Necuparanib (Primary) ; Gemcitabine; Paclitaxel
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms MAP1-A
Sponsors Momenta Pharmaceuticals

Most Recent Events

28 Apr 2020 Primary endpoint (Part B: Overall Survival) has not been met.
28 Apr 2020 Results published in the European Journal of Cancer
21 Jan 2017 Results of an interim futility analysis for phase 2 (n=120, as of Jul 2016), presented at the 2017 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com